# HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study

> **NCT06482008** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 33 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib

## Key facts

- **NCT ID:** NCT06482008
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-19
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-02-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06482008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06482008, "HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06482008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*